Results 81 to 90 of about 184,260 (294)

Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response. [PDF]

, 2016
Adipocytes promote cancer progression and impair treatment, and have been shown to protect acute lymphoblastic leukemia (ALL) cells from chemotherapies. Here we investigate whether this protection is mediated by changes in oxidative stress.
Behan, James W, Heisterkamp, Nora, Ji, Lingyun, Mittelman, Steven D, Parmentier, Jean-Hugues, Sheng, Xia, Tucci, Jonathan   +6 more
core   +1 more source

ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment

Advanced Science, EarlyView.
ETV4 coordinates a dual transcriptional program by upregulating MET and asparagine synthetase (ASNS). The resulting asparagine (Asn) secretion acts as a metabolic signal, reprogramming hepatic stellate cells (HSCs) and primary cancer‐associated fibroblasts (CAFs) toward an inflammatory phenotype. These activated stromal cells release HGF to sustain the
Dujiang Fu, Meijia Zhang, Maoping Cai, Miao Wang, Ziao Huang, Zesheng Lin, Yixin Liu, Wang Qian, Guopeng Chen, Yuxing Liang, Dongyi Wei, Jing xie, Picheng Yan, Yuanyuan Qu, Yongchang Wei   +14 more
wiley   +1 more source

MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia

Technology in Cancer Research & Treatment, 2020
Background: T-cell acute lymphoblastic leukemia is a hematologic malignancy characterized by T-cell proliferation, and in many cases, the ectopic expression of the oncogenic transcription factor T-cell acute lymphocytic leukemia protein 1 (TAL1 ...
Hongbo Sun MD, Zhifu Zhang MD, Wei Luo MD, Junmin Liu MD, Ye Lou MD, Shengmei Xia MD   +5 more
doaj   +1 more source

RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins [PDF]

, 2018
RUNX gene over-expression inhibits growth of primary cells but transforms cells with tumor suppressor defects, consistent with reported associations with tumor progression.
Anderson, Gail, Bell, Margaret, Borland, Gillian, Cameron, Ewan, Gilroy, Kathryn, Hassanudin, Siti Ayuni, Hay, Jodie, Kilbey, Anna, Mackay, Nancy, McDonald, Alma, Neil, James C.   +10 more
core   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia

Haematologica, 2014
Genetic studies in T-cell acute lymphoblastic leukemia have uncovered a remarkable complexity of oncogenic and loss-of-function mutations. Amongst this plethora of genetic changes, NOTCH1 activating mutations stand out as the most frequently occurring ...
Kaat Durinck, Annelynn Wallaert, Inge Van de Walle, Wouter Van Loocke, Pieter-Jan Volders, Suzanne Vanhauwaert, Ellen Geerdens, Yves Benoit, Nadine Van Roy, Bruce Poppe, Jean Soulier, Jan Cools, Pieter Mestdagh, Jo Vandesompele, Pieter Rondou, Pieter Van Vlierberghe, Tom Taghon, Frank Speleman   +17 more
doaj   +1 more source

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. [PDF]

, 2019
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival ...
Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Alousi, Amin M., Arora, Mukta, Askar, Medhat, Auletta, Jeffery J., Bhatt, Vijaya, Bredeson, Christopher, Chhabra, Saurabh, Couriel, Daniel R., Diaz, Miguel Angel, Gadalla, Shahinaz, Gajewski, James, Gale, Robert Peter, Gergis, Usama, Hematti, Peiman, Hemmer, Michael T., Hildebrandt, Gerhard C., Holtan, Shernan G, Inamoto, Yoshihiro, Khandelwal, Pooja, Kitko, Carrie, MacMillan, Margaret L., Majhail, Navneet, Marks, David I., Mehta, Parinda, Mehta, Rohtesh S., Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Pidala, Joseph, Prestidge, Tim, Qayed, Muna, Rangarajan, Hemalatha, Ringden, Olle, Saad, Ayman, Savani, Bipin N., Schultz, Kirk R., Seo, Sachiko, Shah, Ami, Shah, Niketa, Solh, Melhem, Spellman, Stephen R., Spitzer, Thomas, Szer, Jeffrey, Teshima, Takanori, Verdonck, Leo F, Wagner, John, Wang, Tao, Weisdorf, Daniel J., Williams, Kirsten M., Wirk, Baldeep, Yared, Jean A.   +53 more
core   +2 more sources

BCR::ABL1‐Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B‐ALL Cells to Enhancer‐Targeting Drugs

Advanced Science, EarlyView.
Ng et al. show that the BCR::ABL1 kinase that drives the lymphoid leukemia Ph+B‐ALL modulates enhancer function by coopting signaling‐inducible transcription factors such as MYC, STAT5, and ETV5. BCR::ABL1 thereby promotes the transcriptional program driving and defining this leukemia and renders Ph+B‐ALL cells hypersensitive to enhancer‐inhibiting ...
Han Leng Ng, Trudy Lee Glaser, Jintao Zhu, Mark E. Robinson, Kadriye N. Cosgun, Valeriya Malysheva, Ozgen Deniz, Nicholas T. Crump, Kaiyue Helian, Andrew J. Innes, Richard Burt, Li Sun, George John, Haibin Zhou, Atsunori Kaneshige, Longchuan Bai, Shaomeng Wang, Mikhail Spivakov, Markus Müschen, Niklas Feldhahn   +19 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia

Haematologica, 2011
Background Mutations in the PHF6 gene were recently described in patients with T-cell acute lymphoblastic leukemia and in those with acute myeloid leukemia.
Qian Wang, Huiying Qiu, Hui Jiang, Lili Wu, Shasha Dong, Jinlan Pan, Wenjuan Wang, Nana Ping, Jing Xia, Aining Sun, Depei Wu, Yongquan Xue, Hans G. Drexler, Roderick A. F. MacLeod, Suning Chen   +14 more
doaj   +1 more source